TiGenix Achieves First Ever Success In Allogeneic Stem Cell Phase 3 Trial

TiGenix (OTC:TGXSF) – listed on Euronext Brussels under ticker “TIG” – is a leading European stem cell company. The small-cap biotech has already one product on the market (ChondroCelect, an autologous chondrocyte implantation or ACI) and just announced …

[Read the full article here]

Comments are closed.